Improved estimation of overall survival and progression-free survival for state transition modeling

被引:0
|
作者
Wigfield, Peter C. [1 ]
Heeg, Bart [1 ]
Ouwens, Mario [2 ]
机构
[1] Cytel, Weena 316-318, NL-3012 NJ Rotterdam, Netherlands
[2] AstraZeneca, Pepparedsleden 1, S-431 50 Molndal, Sweden
关键词
area between curves; Markov models; optimization; state transition model; PARTITIONED SURVIVAL; CLINICAL-TRIALS;
D O I
10.57264/cer-2023-0031
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Aim: National Institute for Health and Care Excellence guidance (Technical Support Document 19) highlights a key challenge of state transition models (STMs) being their difficulty in achieving a satisfactory fit to the observed within-trial endpoints. Fitting poorly to data over the trial period can then have implications for long-term extrapolations. A novel estimation approach is defined in which the predicted overall survival (OS) and progression-free survival (PFS) extrapolations from an STM are optimized to provide closer estimates of the within-trial endpoints. Materials & methods: An STM was fitted to the SQUIRE trial data in non-small-cell lung cancer (obtained from Project Data Sphere). Two methods were used: a standard approach whereby the maximum likelihood was utilized for the individual transitions and the best-fitting parametric model selected based on AIC/BIC, and a novel approach in which parameters were optimized by minimizing the area between the STM-predicted OS and PFS curves and the corresponding OS and PFS Kaplan-Meier curves. Sensitivity analyses were conducted to assess uncertainty. Results: The novel approach resulted in closer estimations to the OS and PFS Kaplan-Meier for all combinations of parametric distributions analyzed compared with the standard approach. Though the uncertainty associated with the novel approach was slightly larger, it provided better estimates to the restricted mean survival time in 10 of the 12 parametric distributions analyzed. Conclusion: A novel approach is defined which provides an alternative STM estimation method enabling improved fits to modeled endpoints, which can easily be extended to more complex model structures. Plain language summary: A key challenge of state transition models is their difficulty in achieving a satisfactory fit to the observed within-trial endpoints (such as overall survival [OS] and progressionfree survival [PFS]). This can have implications for long-term extrapolations and, therefore, for medical decision making as well. A novel approach is defined which provides an alternative estimation method that enables improved fits to modeled endpoints. This approach resulted in closer estimations to the OS and PFS Kaplan-Meier curves for all combinations of parametric distributions analyzed compared with the standard approach. This addresses some of the challenges that are discussed when modeling state transition models, and can easily be extended to more complex model structures. Tweetable abstract: A key challenge of state transition models is their difficulty in achieving a satisfactory fit to the observed within -trial endpoints, with implications for long-term extrapolations and medical decision making. In this new Methodology article, the authors explore a novel method that helps address some of these challenges.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] IMPROVED ESTIMATION OF OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL FOR STATE TRANSITION MODELLING IN ONCOLOGY
    Wigfield, P.
    Heeg, B.
    Ouwens, M.
    VALUE IN HEALTH, 2022, 25 (12) : S6 - S6
  • [2] Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model
    Fu, Haoda
    Wang, Yanping
    Liu, Jingyi
    Kulkarni, Pandurang M.
    Melemed, Allen S.
    STATISTICS IN MEDICINE, 2013, 32 (02) : 240 - 254
  • [3] A Weibull multi-state model for the dependence of progression-free survival and overall survival
    Li, Yimei
    Zhang, Qiang
    STATISTICS IN MEDICINE, 2015, 34 (17) : 2497 - 2513
  • [4] Concordance index: Surrogacy of progression-free survival for overall survival
    Fan, Yiwei
    Yin, Guosheng
    CONTEMPORARY CLINICAL TRIALS, 2021, 104
  • [5] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Joint modeling of progression-free and overall survival and computation of correlation measures
    Meller, Matthias
    Beyersmann, Jan
    Rufibach, Kaspar
    STATISTICS IN MEDICINE, 2019, 38 (22) : 4270 - 4289
  • [7] TO JOIN OR NOT TO JOIN? ANALYSIS OF PROGRESSION-FREE AND OVERALL SURVIVAL USING MULTI-STATE MODELING
    Rael, M.
    Ishak, K. J.
    Benedict, A.
    VALUE IN HEALTH, 2016, 19 (03) : A107 - A107
  • [8] Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial
    Redman, Mary W.
    Goldman, Bryan H.
    LeBlanc, Michael
    Schott, Anne
    Baker, Laurence H.
    CLINICAL CANCER RESEARCH, 2013, 19 (10) : 2646 - 2656
  • [9] JOINT ESTIMATION OF PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL
    Ouwens, M. J.
    Bergman, G.
    VALUE IN HEALTH, 2012, 15 (07) : A462 - A462
  • [10] Progression-free survival as a surrogate for overall survival in advanced cancer.
    Gillies, Eric
    Holdai, Veera
    Cowall, David Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)